Christopher. G. Goetz
#96,051
Most Influential Person Now
Christopher. G. Goetz's AcademicInfluence.com Rankings
Christopher. G. Goetzphilosophy Degrees
Philosophy
#3639
World Rank
#5848
Historical Rank
Logic
#1297
World Rank
#2009
Historical Rank
Christopher. G. Goetzbiology Degrees
Biology
#4596
World Rank
#6833
Historical Rank
Neuroscience
#488
World Rank
#507
Historical Rank
Download Badge
Philosophy Biology
Why Is Christopher. G. Goetz Influential?
(Suggest an Edit or Addition)Christopher. G. Goetz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results (2008) (4378)
- MDS clinical diagnostic criteria for Parkinson's disease (2015) (3560)
- Diagnosis and management of dementia with Lewy bodies (2005) (3346)
- Clinical diagnostic criteria for dementia associated with Parkinson's disease (2007) (2413)
- Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (2382)
- Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease (2004) (1771)
- A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease (2003) (1457)
- Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan (2007) (1068)
- Core assessment program for intracerebral transplantations (CAPIT) (1992) (1042)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease (2011) (1005)
- SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders (2003) (971)
- Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force (2007) (918)
- MDS research criteria for prodromal Parkinson's disease (2015) (897)
- Missing pieces in the Parkinson's disease puzzle (2010) (697)
- Prevalence of parkinsonian signs and associated mortality in a community population of older people. (1996) (661)
- Depression rating scales in Parkinson's disease: Critique and recommendations (2007) (616)
- Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. (2003) (538)
- How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale (2013) (534)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease (2011) (493)
- Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group (2007) (450)
- Risk factors for nursing home placement in advanced Parkinson's disease (1993) (448)
- Levodopa‐induced dyskinesias (2007) (419)
- Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease (1999) (397)
- Priorities in Parkinson's disease research (2011) (391)
- Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease (2014) (384)
- Neurosurgical horizons in Parkinson's disease (1993) (371)
- Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 (2005) (371)
- DLB and PDD boundary issues (2007) (351)
- Treatment of ADHD in children with tics: a randomized controlled trial. (2002) (351)
- Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) (1996) (337)
- A 12-year population-based study of psychosis in Parkinson disease. (2010) (333)
- Age at onset in two common neurodegenerative diseases is genetically controlled. (2002) (332)
- The history of Parkinson's disease: early clinical descriptions and neurological therapies. (2011) (322)
- Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. (1998) (316)
- Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. (2000) (314)
- Complete genomic screen in Parkinson disease: evidence for multiple genes. (2001) (302)
- Accuracy of the Clinical Diagnosis of Corticobasal Degeneration (1997) (298)
- Apathy and anhedonia rating scales in Parkinson's disease: Critique and recommendations (2008) (292)
- Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessment (1994) (287)
- Treatment interventions for Parkinson's disease: an evidence based assessment (2002) (280)
- Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced Parkinson's disease. (1989) (274)
- Hallucinations in Parkinson disease (2009) (269)
- Mortality and hallucinations in nursing home patients with advanced Parkinson's disease (1995) (264)
- Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: Focused review and a new integrative model (2005) (261)
- Letter: Myoclonus, methysergide, and serotonin. (1974) (258)
- Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial (2007) (250)
- Health‐related quality‐of‐life scales in Parkinson's disease: Critique and recommendations (2011) (245)
- Anxiety rating scales in Parkinson's disease: Critique and recommendations (2008) (242)
- Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. (1999) (228)
- Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions (2008) (226)
- Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double‐blind, randomized, controlled trial (2015) (225)
- Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations (2010) (225)
- Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. (2003) (224)
- Physical therapy and Parkinson's disease (1994) (222)
- Longitudinal outcome of Parkinson’s disease patients with psychosis (2003) (219)
- Reduced working memory span in Parkinson's disease: Evidence for the role of frontostriatal system in working and strategic memory. (1996) (214)
- Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease (2003) (212)
- Objective assessments of longitudinal outcome in Gilles de la Tourette’s syndrome (2003) (210)
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. (2014) (205)
- A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease (2007) (204)
- Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease (2010) (203)
- Hypersexuality with antiparkinsonian therapy. (1989) (201)
- What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. (1997) (200)
- Factor structure of the unified Parkinson's disease rating scale: Motor examination section (1998) (198)
- Intact mirror-tracing and impaired rotary-pursuit skill learning in patients with Huntington's disease: evidence for dissociable memory systems in skill learning. (1997) (194)
- Pain in Parkinson's disease (1986) (193)
- Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. (2001) (190)
- Tardive dyskinesia: review and update. (1980) (190)
- The Unified Dyskinesia Rating Scale: Presentation and clinimetric profile (2008) (187)
- Altered cortical visual processing in PD with hallucinations (2004) (184)
- Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis (2008) (184)
- Measurement instruments to assess posture, gait, and balance in Parkinson's disease: Critique and recommendations (2016) (179)
- Clinical presentation and pharmacological therapy in corticobasal degeneration. (1998) (174)
- FMR1 CGG repeat length predicts motor dysfunction in premutation carriers (2008) (173)
- Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study) (2004) (172)
- United Parkinson Foundation Neurotransplantation Registry on adrenal medullary transplants (1991) (171)
- Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease (1999) (169)
- Intravenous levodopa in hallucinating Parkinson's disease patients (1998) (167)
- Advantages of a modified scoring method for the rush video‐based tic rating scale (1999) (167)
- Prospective longitudinal assessment of hallucinations in Parkinson’s disease (2001) (167)
- Expanded and independent validation of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (2012) (164)
- Objective changes in motor function during placebo treatment in PD (2000) (164)
- Clonidine and Gilles de la Tourette's syndrome: Double‐blind study using objective rating methods (1987) (162)
- Scales to assess psychosis in Parkinson's disease: Critique and recommendations (2008) (158)
- Hallucinations in Parkinson disease in the prelevodopa era (2006) (157)
- Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at‐home testing device (2009) (155)
- Teaching tape for the motor section of the toronto western spasmodic torticollis scale (1997) (154)
- Validation of the MDS clinical diagnostic criteria for Parkinson's disease (2018) (153)
- Early dopaminergic drug-induced hallucinations in parkinsonian patients (1998) (152)
- Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale (1997) (151)
- Putative chromaffin cell survival and enhanced host‐derived TH‐Fiber innervation following a functional adrenal medulla autograft for Parkinson's disease (1991) (151)
- Decreased color discrimination and contrast sensitivity in Parkinson’s disease (2000) (150)
- Charcot: Constructing Neurology (1995) (148)
- Olanzapine and clozapine (2000) (147)
- Dysautonomia rating scales in Parkinson's disease: Sialorrhea, dysphagia, and constipation—Critique and recommendations by movement disorders task force on rating scales for Parkinson's disease (2009) (147)
- Double‐blind, placebo‐controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on‐off' fluctuations (1993) (146)
- Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. (2002) (145)
- The past, present, and future of telemedicine for Parkinson's disease (2014) (142)
- The malignant course of "benign hallucinations" in Parkinson disease. (2006) (141)
- Poor visual discrimination and visual hallucinations in Parkinson's disease. (1998) (140)
- Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society‐unified Parkinson's disease rating scale scores (2012) (140)
- Apolipoprotein E controls the risk and age at onset of Parkinson disease (2004) (140)
- Bupropion in Parkinson's disease (1984) (138)
- Environmental factors and Parkinson's disease (1989) (133)
- Autonomic dysfunction in Parkinson's disease (1986) (132)
- Dystonia rating scales: Critique and recommendations (2013) (131)
- Task force report: Scales for screening and evaluating tremor: Critique and recommendations (2013) (130)
- Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. (2000) (129)
- Fragile X–associated tremor/ataxia syndrome in sisters related to X‐inactivation (2005) (127)
- Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. (2003) (127)
- Botulinum toxin injection for spasmodic torticollis (1992) (124)
- Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. (2014) (124)
- Open‐label flexible‐dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease (2006) (123)
- Global scales for cognitive screening in Parkinson's disease: Critique and recommendations (2018) (123)
- Pharmacology of hallucinations induced by long-term drug therapy. (1982) (123)
- Placebo‐associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease (2002) (123)
- Therapeutic approaches. (2000) (121)
- Placebo influences on dyskinesia in Parkinson's disease (2008) (120)
- Amyotrophic lateral sclerosis: Early contributions of Jean‐Martin Charcot (2000) (116)
- Evaluation of a modified inverted walking stick as a treatment for Parkinsonian freezing episodes (1990) (114)
- Switching dopamine agonists in advanced Parkinson’s disease (1999) (111)
- Respiratory dyskinesias: extrapyramidal dysfunction and dyspnea. (1978) (111)
- Adult tics in Gilles de la Tourette's syndrome (1992) (110)
- A pure parkinsonian syndrome following acute carbon monoxide intoxication. (1982) (109)
- Dopaminergic Transplants in Patients with Parkinson's Disease: Neuroanatomical Correlates of Clinical Recovery (1997) (109)
- Diagnosing PD‐MCI by MDS task force criteria: How many and which neuropsychological tests? (2015) (108)
- The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II (2007) (106)
- Pharmacological therapy in progressive supranuclear palsy. (1998) (105)
- Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease (2013) (105)
- Hallucinations and sleep disorders in PD (2005) (104)
- Validation of the Italian version of the Movement Disorder Society—Unified Parkinson’s Disease Rating Scale (2013) (103)
- Single-blind clinical trial of psychotherapy for treatment of psychogenic movement disorders. (2006) (103)
- Short-term and practice effects of metronome pacing in Parkinson's disease patients with gait freezing while in the 'on' state: randomized single blind evaluation. (2004) (101)
- Charcot on Parkinson's disease (1986) (100)
- Levodopa-induced myoclonus. (1975) (99)
- “On” freezing in Parkinson's disease: Resistance to visual cue walking devices (2000) (99)
- Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations (2010) (99)
- Movement disorder society criteria for clinically established early Parkinson's disease (2018) (96)
- Tremor and ataxia in fragile X premutation carriers: Blinded videotape study (2003) (96)
- Clinical differences among mild cognitive impairment subtypes in Parkinson's disease (2012) (95)
- Validation of the MDS‐UPDRS Part I for nonmotor symptoms in Parkinson's disease (2012) (95)
- Assessing the non‐motor symptoms of Parkinson's disease: MDS‐UPDRS and NMS Scale (2015) (94)
- A Phase 2A Trial of the Novel mGluR5‐Negative Allosteric Modulator Dipraglurant for Levodopa‐Induced Dyskinesia in Parkinson's Disease (2016) (93)
- Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. (2001) (92)
- Wearing‐off scales in Parkinson's disease: Critique and recommendations (2011) (92)
- Progression of gait, speech and swallowing deficits in progressive supranuclear palsy (2003) (92)
- Neuropathic features in fragile X premutation carriers (2007) (92)
- The placebo treatments in neurosciences (2008) (88)
- A rating scale for Gilles de la Tourette's syndrome (1987) (87)
- Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: A double blind video‐based analysis (2009) (86)
- Wheeled and standard walkers in Parkinson's disease patients with gait freezing. (2003) (86)
- Differential progression of motor impairment in levodopa‐treated Parkinson's disease (2000) (86)
- Rating scale for psychogenic movement disorders: Scale development and clinimetric testing (2005) (85)
- Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor (2013) (85)
- Risk factors for progression in Parkinson's disease (1988) (85)
- Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off‐state (1999) (85)
- Determinants of quality of life in children with Gilles de la Tourette syndrome (2009) (84)
- Teaching tape for the motor section of the unified Parkinson's disease rating scale (1995) (84)
- Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease (1990) (83)
- Disability Rating Scales in Parkinson's Disease: Critique and Recommendations (2016) (81)
- Parkinson's disease‐related fatigue: A case definition and recommendations for clinical research (2016) (81)
- Visual plus nonvisual hallucinations in Parkinson's disease: Development and evolution over 10 years (2011) (79)
- Dopaminergic agonists in the treatment of Parkinson's disease (1990) (78)
- Systematic review of severity scales and screening instruments for tics: Critique and recommendations (2017) (78)
- Alpha-tocopherol in the ventricular cerebrospinal fluid of Parkinson's disease patients (1996) (78)
- Hallucinations and sleep disorders in PD (2005) (77)
- Assuring interrater reliability for the UPDRS motor section: Utility of the UPDRS teaching tape (2004) (76)
- Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies (2008) (76)
- Which dyskinesia scale best detects treatment response? (2013) (75)
- The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I (2007) (75)
- The new definition and diagnostic criteria of Parkinson's disease (2016) (74)
- A responsive outcome for Parkinson's disease neuroprotection futility studies (2005) (71)
- Chronic agonist therapy for Parkinson's disease (1985) (71)
- Fibroblast phenotype in male carriers of FMR1 premutation alleles. (2010) (71)
- Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient (2016) (70)
- Clonidine and clonazepam in Tourette syndrome. (1992) (69)
- Teaching program for the movement disorder society‐sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS‐UPDRS) (2010) (67)
- Akathisia in Parkinson's disease (1994) (66)
- Are patients with Parkinson’s disease blind to blindsight? (2014) (65)
- Coping strategies for visual hallucinations in Parkinson's disease (2003) (64)
- Differences in MDS‐UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration (2016) (63)
- Dissociations among daytime sleepiness, nighttime sleep, and cognitive status in Parkinson's disease. (2013) (63)
- Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. (2003) (62)
- Application of the unified Parkinson's disease rating scale in progressive supranuclear palsy: Factor analysis of the motor scale (2000) (62)
- Visual hallucinations induced by deep brain stimulation in Parkinson's disease. (2000) (62)
- Delayed recognition memory in Parkinsons disease: a role for working memory? (1999) (62)
- Blinded evaluation confirms long‐term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease (1992) (61)
- Continuous in-home monitoring of essential tremor. (2014) (61)
- What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study (1997) (60)
- Contribution of Jules Froment to the study of Parkinsonian rigidity (2007) (60)
- The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. (1988) (60)
- Fatigue in Parkinson’s disease: report from a mutidisciplinary symposium (2016) (60)
- The MDS-UPDRS Part II (motor experiences of daily living) resulted useful for assessment of disability in Parkinson's disease. (2013) (57)
- Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long‐term worsening (2008) (57)
- Relationships among pain, depression, and sleep alterations in Parkinson's disease. (1987) (56)
- The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension (2011) (56)
- Fluphenazine and multifocal tic disorders. (1984) (56)
- Apolipoprotein E gene polymorphism, total plasma cholesterol level, and Parkinson disease dementia. (2007) (56)
- Hyperkinetic movement disorders misdiagnosed as tics in gilles de la tourette syndrome (1998) (55)
- Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics (2002) (55)
- Genetic polymorphisms in Parkinson disease subjects with and without hallucinations: an analysis of the cholecystokinin system. (2004) (54)
- Historical underpinnings of the term essential tremor in the late 19th century (2008) (54)
- Entorhinal cortex atrophy differentiates Parkinson's disease patients with and without dementia (2012) (52)
- Relationship between the MDS‐UPDRS domains and the health‐related quality of life of Parkinson's disease patients (2014) (52)
- I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging (2014) (52)
- Efficacy of a patient‐training videotape on motor fluctuations for on‐off diaries in parkinson's disease (1997) (51)
- Gilles de la Tourette on Tourette syndrome. (1982) (51)
- Tourette syndrome: pieces of the puzzle. (2001) (51)
- TikTok Tics: A Pandemic Within a Pandemic (2021) (51)
- Clinical validation of movement disorder society–recommended diagnostic criteria for Parkinson's disease with dementia (2012) (50)
- An update expert opinion on management and research strategies in Parkinson's disease psychosis (2011) (50)
- A longitudinal program for biomarker development in Parkinson's disease: A feasibility study (2009) (50)
- [Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS): a new scale for the evaluation of Parkinson's disease]. (2010) (49)
- Home alone: Methods to maximize tic expression for objective videotape assessments in Gilles de la Tourette syndrome (2001) (48)
- Controlled‐release carbidopa/levodopa (CR4‐Sinemet) in Parkinson's disease patients with and without motor fluctuations (1988) (48)
- Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. (2021) (47)
- Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation (1996) (47)
- Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. (2018) (47)
- Amantadine and motor fluctuations in chronic Parkinson's disease. (1987) (47)
- Impaired Frontostriatal Cognitive Functioning Following Posteroventral Pallidotomy in Advanced Parkinson's Disease (2000) (47)
- Standardized training tools for the UPDRS activities of daily living scale: Newly available teaching program (2003) (46)
- Ballistic-choreic movements as the presenting feature of renal cancer. (2001) (46)
- Hallucinations in Parkinson's disease: the clinical syndrome. (1999) (46)
- Pergolide mesylate and idiopathic Parkinson disease (1982) (45)
- Abolishing the 1‐year rule: How much evidence will be enough? (2016) (45)
- Rating scales for dyskinesias in Parkinson's disease. (1999) (45)
- Safety of rasagiline in elderly patients with Parkinson disease (2006) (45)
- Hemiparkinsonism with hemiatrophy (1988) (44)
- Relationships among cognitive impairment, sleep, and fatigue in Parkinson's disease using the MDS-UPDRS. (2014) (44)
- Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations (2012) (43)
- Trauma and movement disorders. (1992) (42)
- Movement Disorder Society Unified Parkinson Disease Rating Scale experiences in daily living: Longitudinal changes and correlation with other assessments (2013) (41)
- Levodopa stability in solution: Time course, environmental effects, and practical recommendations for clinical use (1996) (41)
- Parkinson's disease and motor fluctuations (1987) (41)
- Initial management of Parkinson’s disease (2014) (41)
- Cholinergic mechanisms in Tourette syndrome (1982) (41)
- Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations (2016) (39)
- Progression of Parkinson's disease without levodopa (1987) (39)
- Delayed onset of progressive dystonia following subacute 3‐nitropropionic acid treatment in Cebus apella monkeys (2000) (39)
- The Parkinson's disease e‐diary: Developing a clinical and research tool for the digital age (2019) (38)
- Huntington's disease. (1979) (38)
- Telemedicine vs Office Visits in a Movement Disorders Clinic: Comparative Satisfaction of Physicians and Patients (2018) (37)
- Force Control Deficits in Individuals with Parkinson’s Disease, Multiple Systems Atrophy, and Progressive Supranuclear Palsy (2013) (37)
- Effect of Stereotaxic Intrastriatal Cografts of Autologous Adrenal Medulla and Peripheral Nerve in Parkinson's Disease: Two-Year Follow-up Study (1997) (37)
- There is a renaissance of interest in pallidotomy for Parkinson's disease (1996) (37)
- New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease (2010) (37)
- Jean-Martin Charcot and his vibratory chair for Parkinson disease (2009) (37)
- Blood levodopa levels and Unified Parkinson's Disease Rating Scale function (1993) (37)
- Genetic variability of the CYP 2D6 gene is not a risk factor for sporadic Parkinson's disease (1996) (36)
- Impact of placebo assignment in clinical trials of Parkinson's disease (2003) (35)
- Primary writing tremor (1982) (35)
- Talipexole and adult Gilles de la tourette's syndrome: Double‐blind, placebo‐controlled clinical trial (1994) (35)
- Official Japanese Version of the International Parkinson and Movement Disorder Society–Unified Parkinson's Disease Rating Scale: Validation Against the Original English Version (2014) (35)
- Rating Scales in Parkinson's Disease: Clinical Practice and Research (2012) (35)
- Corticobasal Degeneration and Related Disorders (1999) (34)
- Amphetamine‐induced hypersensitivity in guinea pigs (1979) (34)
- Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations (2019) (34)
- Early morning off-medication dyskinesias, dystonia, and choreic subtypes. (2001) (34)
- Agonist substitution in advanced Parkinson's disease (1989) (34)
- Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations (2016) (34)
- Parkin mutations in a patient with hemiparkinsonism–hemiatrophy: A clinical–genetic and PET study (2002) (33)
- Skin rash associated with Sinemet 25/100. (1983) (33)
- Validation study of the hoehn and yahr scale included in the MDS‐UPDRS (2018) (32)
- Handling missing values in the MDS‐UPDRS (2015) (32)
- Tardive Dyskinesia: Pharmacology and Clinical Implications (1982) (32)
- Drug-induced Parkinsonism and idiopathic Parkinson's disease. (1983) (32)
- Treatment of ADHD in children with tics (2002) (32)
- Assessing Bradykinesia in Parkinsonian Disorders (2013) (31)
- The pharmacology of olivopontocerebellar atrophy. (1984) (31)
- Transcultural comparison of psychogenic movement disorders (2005) (31)
- Failing as doorman and disc jockey at the same time: Amygdalar dysfunction in Parkinson's disease (2016) (30)
- Parkinson's disease: Is it a consequence of human brain evolution? (2019) (30)
- Impact of Alzheimer's-type dementia and information source on the assessment of depression (1995) (29)
- Levodopa and presymptomatic detection of Huntington's disease--eight-year follow-up. (1980) (29)
- Evaluating Parkinson's disease patients at home: Utility of self‐videotaping for objective motor, dyskinesia, and ON–OFF assessments (2008) (29)
- CLINICAL RATING AND QUANTITATIVE ASSESSMENT OF TICS (1997) (29)
- Age‐related influences on the clinical characteristics of new‐onset hallucinations in Parkinson's disease patients (2006) (29)
- Clinimetric testing of the comprehensive cervical dystonia rating scale (2016) (28)
- Adrenal medullary autografts in patients with Parkinson's disease. (1989) (28)
- Myoclonus and Epilepsy in Childhood (1997) (28)
- Speech therapy in Parkinson's disease (2002) (28)
- Non-linearity of Parkinson’s disease progression: implications for sample size calculations in clinical trials (2005) (28)
- Anticholinergic therapies in the treatment of Parkinson's disease (2002) (28)
- History of the extensor plantar response: Babinski and Chaddock signs. (2002) (28)
- Using global statistical tests in long‐term Parkinson's disease clinical trials (2009) (27)
- Accuracy of the clinical diagnosis of postencephalitic parkinsonism: a clinicopathologic study (1998) (27)
- Drug-induced movement disorders. (1998) (27)
- Rating scales for cognition in Huntington's disease: Critique and recommendations (2018) (27)
- Effects of head trauma from motor vehicle accidents on Parkinson's disease (1991) (27)
- Motor function in Parkinson's disease and supranuclear palsy: simultaneous factor analysis of a clinical scale in several populations (2006) (27)
- Presymptomatic and early detection in Huntington's disease (1980) (27)
- IPMDS‐Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS‐UPDRS and UDysRS (2014) (27)
- Rating scales and quantitative assessment of tics. (2001) (27)
- On the mechanism of sudden death in Moersch‐Woltman syndrome (1983) (27)
- Drug-induced extrapyramidal disorders - a neuropsychiatric interface. (1981) (26)
- Complications of chronic levodopa therapy (1981) (26)
- Genetic and Clinical Predictors of Deep Brain Stimulation in Young‐Onset Parkinson's Disease (2016) (26)
- Scales to evaluate psychosis in Parkinson's disease. (2009) (26)
- History of dystonia: Part 4 of the MDS‐sponsored history of movement disorders exhibit, Barcelona, June, 2000 (2001) (26)
- Movement disorders associated with encephalitis lethargica: A video compilation (2006) (26)
- Movement disorders caused by medical disease. (2009) (26)
- Charcot, the Clinician: The Tuesday Lessons: Excerpts from Nine Case Presentations on General Neurology Delivered at the Salpetriere Hospital in 1887-88 (1987) (26)
- An early photographic case of probable progressive supranuclear palsy (1996) (26)
- Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial (2019) (25)
- Cross‐Cultural Differences of the Non‐Motor Symptoms Studied by the Traditional Chinese Version of the International Parkinson and Movement Disorder Society–Unified Parkinson's Disease Rating Scale (2017) (25)
- Epidemiology and pathophysiology of tardive dyskinesias. (1988) (25)
- 5-Hydroxytryptophan-induced myoclonus in guinea pigs: mediation through 5-HT1/2 receptor subtypes. (1998) (25)
- Levodopa reduces the growth promoting effects of striatal extracts on rostral mesencephalic tegmentum cultures (1991) (25)
- Special Issue: Selected Essays From the American Academy of Neurology Educational Program, 2001 (2002) (25)
- Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. (1993) (25)
- Efficacy of cervical cord stimulation in dystonia. (1988) (24)
- Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects (2006) (24)
- Temporal stability of the Unified Dyskinesia Rating Scale (2011) (24)
- Development and progression of motor fluctuations and side effects in Parkinson's disease: comparison of Sinemet CR versus carbidopa/levodopa. (1989) (23)
- What is it? case 1, 1996: Rapidly progressive parkinsonism, incontinence, impotency, and levodopa‐induced moaning in a patient with multiple myeloma (1996) (23)
- Drug holiday in the management of Parkinson disease. (1982) (23)
- Telemedicine Use for Movement Disorders: A Global Survey. (2018) (23)
- Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations (2018) (23)
- Movement Disorder Society–Unified Parkinson's Disease Rating Scale Use in the Covid‐19 Era (2020) (22)
- Effect of chronic levodopa on haloperidol-induced behavioral supersensitivity in the guinea pig. (1981) (22)
- Weekly drug holiday in Parkinson disease (1981) (22)
- Pergolide in Parkinson's disease. (1983) (22)
- The effect of antimuscarinic agents on haloperidol induced behavioral hypersensitivity. (1986) (22)
- Neurologic health outcomes and Agent Orange (1994) (22)
- Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome (2001) (22)
- United Parkinson Foundation Neurotransplantation Registry: multicenter US and Canadian data base, presurgical and 12 month follow-up. (1990) (22)
- Influence of COMT inhibition on levodopa pharmacology and therapy (1998) (22)
- Visual art in the neurologic career of Jean-Martin Charcot. (1991) (21)
- The pathophysiology of tardive dyskinesia. (1985) (20)
- Neurology for the Non-Neurologist (1981) (20)
- John Hughlings Jackson: Father of English Neurology (1999) (20)
- Part 1: The history of 19th century neurology and the American Neurological Association (2003) (20)
- Rating Scales and Performance‐based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations (2018) (20)
- Scales to Assess Clinical Features of Progressive Supranuclear Palsy: MDS Task Force Report (2015) (20)
- The origins of scientific cinematography and early medical applications (2004) (20)
- Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Health‐Related Quality of Life and Caregiver Quality of Life (2018) (20)
- Amantadine and other antiglutamate agents (2002) (19)
- Physical therapy in Parkinson's disease (1995) (19)
- Studies on the interaction of reserpine, d-amphetamine, apomorphine and 5-hydroxytryptophan. (2009) (19)
- Chapter 15: Jean-Martin Charcot and the anatomo-clinical method of neurology. (2010) (19)
- Charcot and Parkinson's Disease (2002) (19)
- Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies (2008) (19)
- The Progressive Supranuclear Palsy Clinical Deficits Scale (2020) (18)
- Parkinson disease and STN-DBS: cognitive effects in GBA mutation carriers. (2022) (18)
- Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation (2017) (18)
- Association between antipsychotics and body mass index when treating patients with tics. (2010) (18)
- Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease (2014) (18)
- Poor Beard!! (2001) (17)
- Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson’s disease (2003) (17)
- The history of Parkinson's disease: Part 2 of the MDS‐sponsored History of Movement Disorders exhibit, Barcelona, June, 2000 (2001) (17)
- Relationship of Aluminum to Neurocognitive Dysfunction in Chronic Dialysis Patients (1988) (17)
- Treatment of depression in idiopathic Parkinson's disease (2002) (17)
- Pergolide mesylate (1985) (17)
- [Visual hallucinations in Parkinson and Charles Bonnet Syndrome patients. A phenomenological and pathogenetic comparison]. (2000) (17)
- Concurrent treatment with benztropine and haloperidol attenuates development of behavioral hypersensitivity but not dopamine receptor proliferation. (1988) (17)
- Neurotoxins in Clinical Practice (1986) (17)
- Dystonic posturing in temporal lobe seizures (1989) (16)
- History of chorea: Part 3 of the MDS‐sponsored history of movement disorders exhibit, Barcelona, June 2000 (2001) (16)
- Gilles de la tourette syndrome and compressive neuropathies (1980) (16)
- Item Response Theory Analysis of the MDS‐UPDRS Motor Examination: Tremor vs. Nontremor Items (2020) (16)
- Vibration therapy for Parkinson's disease: Charcot's studies revisited. (2012) (16)
- Predicting Parkinson's disease. Discussion (1990) (16)
- History of tic disorders and Gilles de la Tourette syndrome: Part 5 of the MDS‐sponsored history of movement disorders exhibit, Barcelona, June 2000 (2001) (16)
- Charcot, hysteria, and simulated disorders. (2016) (16)
- Lergotrile in the treatment of parkinsonism (1978) (16)
- Treatment of tremor and dystonia. (2001) (16)
- Neuropharmacology in the elderly. (1998) (15)
- New lessons from old drugs (1998) (15)
- Early American neurologic textbooks (1995) (15)
- What influences placebo and nocebo responses in Parkinson's disease? (2018) (15)
- Compressive neuropathies in Tourette syndrome. (1982) (15)
- Chapter 1: The Pharmacology of Schizophrenia (1976) (15)
- Treatment of advanced Parkinson's disease: an evidence-based analysis. (2003) (14)
- Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations (2018) (14)
- Seminal figures in the history of movement disorders: Gilles de la Tourette, Oppenheim, the Vogts, von Economo, Wilson, and Marsden Part 12 of the MDS‐sponsored History of Movement Disorders exhibit, Barcelona, June 2000 (2001) (14)
- Drugs to treat dementia and psychosis (2002) (14)
- Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example. (2014) (14)
- A practical approach to remote longitudinal follow‐up of Parkinson's disease: The FOUND study (2014) (14)
- Drug‐induced asterixis in Parkinson disease (1982) (14)
- Pergolide mesylate: four years experience in Parkinson's disease. (1987) (14)
- Charcot and the myth of misogyny. (1999) (13)
- Re: UPDRS: Status and recommendations (2004) (13)
- Unified Parkinson’s Disease Rating Scale (UPDRS) and Movement Disorder Society Revision of the UPDRS (MDS-UPDRS) (2012) (13)
- Animal models of tardive dyskinesias. (1983) (13)
- Rating Scales in Parkinson's Disease (2012) (13)
- The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD) (1998) (13)
- Bromocriptine‐induced myoclonus (1987) (13)
- The first miracle in neurodegenerative disease: The discovery of oral levodopa (1999) (13)
- What's new? Clinical progression and staging of Parkinson's disease. (2006) (13)
- MAO‐B inhibitors for the treatment of Parkinson's disease (2002) (13)
- Clinical Neurological Phenotype of FXTAS (2010) (13)
- Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations (2011) (13)
- Jean‐Martin Charcot and Silas Weir Mitchell (1997) (13)
- Drug-induced myoclonus. (1986) (13)
- Battle of the titans (2000) (13)
- Dopamine dysregulation syndrome item from the MDS‐UPDRS (2012) (12)
- Pierre Marie: Gifted Intellect, Poor Timing and Unchecked Emotionality (2003) (12)
- The Mechanism of Human Facial Expression (Studies in Emotion and Social Interaction) (1991) (12)
- William Osler: On Chorea: On Charcot (2000) (12)
- The autonomic nervous system in Gilles de la Tourette's syndrome (1987) (12)
- Complete genomic screen in Parkinson Disease (2001) (12)
- Clinimetric Properties of the Fragile X‐associated Tremor Ataxia Syndrome Rating Scale (2019) (12)
- Textbook of Clinical Neuropharmacology and Therapeutics (1992) (12)
- The Evolution-Driven Signature of Parkinson’s Disease (2020) (12)
- Early american professorships in neurology (1996) (12)
- Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease (2017) (12)
- Jean-Martin Charcot and the aging brain. (2002) (12)
- Neuroleptic-induced dopamine hyposensitivity. (1984) (11)
- The Salpêtrière in the wake of Charcot's death. (1987) (11)
- Teaching program for the Unified Dyskinesia Rating Scale (2009) (11)
- Speech abnormalities in tardive dyskinesia. (1984) (11)
- Turkish Standardization of Movement Disorders Society Unified Parkinson's Disease Rating Scale and Unified Dyskinesia Rating Scale (2018) (11)
- Dopaminergic agonists in the treatment of Parkinson's disease. (1990) (11)
- Unified Parkinson’s Disease Rating Scale (UPDRS) and The Movement-Disorder Society Sponsored-unified Parkinson’s Disease Rating Scale (MDS-UPDRS) (2010) (11)
- Movement disorders in kuru (1999) (11)
- Ideational fluency in Parkinson's disease (1992) (11)
- Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers (2022) (11)
- Dystonia secondary to Sjögren–Larsson syndrome (2000) (11)
- Comparison of tic characteristics between children and adults (2008) (11)
- Postural Directionality and Head Tremor in Cervical Dystonia (2020) (11)
- Does seasonal variation affect hallucinations in PD? a longitudinal study (2006) (11)
- Selegiline HCl : selective MAO-type B inhibitor. Discussion (1990) (11)
- Clinical improvement in parkinsonian patients undergoing adrenal to caudate transplantation is not reflected by chromogranin a or basic fibroblast growth factor in ventricular fluid (1991) (10)
- Topiramate as an adjunct to amantadine in the treatment of dyskinesia in parkinson's disease: A randomized, double‐blind, placebo‐controlled multicenter study (2017) (10)
- Levodopa-free periods ("drug holidays") in the management of parkinsonism. (1983) (10)
- Animal models of tardive dyskinesia: their use in the search for new treatment methods. (1983) (10)
- Tourette syndrome. Clinical rating and quantitative assessment of tics. (1997) (10)
- J.-M. Charcot and simulated neurologic disease (2007) (10)
- Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
- Reducing Dosing Frequency of Carbidopa/Levodopa: Double-Blind Crossover Study Comparing Twice-Daily Bilayer Formulation of Carbidopa/Levodopa (IPX054) Versus 4 Daily Doses of Standard Carbidopa/Levodopa in Stable Parkinson Disease Patients (2009) (9)
- Charcot as therapeutic interventionist and treating neurologist (1995) (9)
- New Strategies with Dopaminergic Drugs: Modified Formulations of Levodopa and Novel Agonists (1997) (9)
- Validation of the Polish version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). (2020) (9)
- Gilles de la tourette's syndrome in twins: Clinical and neurochemical data (1990) (9)
- Induction of parkinsonism by intraventricular bethanechol in a patient with Alzheimer's disease (1989) (8)
- History of Parkinson's disease. (2007) (8)
- Neuropsychological and Behavioral Aspects of Transplants in Parkinson's Disease and Huntington's Disease (2000) (8)
- Surgical treatment for Parkinson's disease: Deep brain surgery (2002) (8)
- Treatment with fetal allografts (1997) (8)
- The prefaces by Charcot (2003) (8)
- Nineteenth century studies of atypical parkinsonism: Charcot and his Salpêtrière School. (2000) (8)
- A 6-month trial of pergolide mesylate in the treatment of idiopathic Parkinson's disease. (1983) (8)
- Erratum: Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease (Human Molecular Genetics (2003) vol. 12 (3259-3267)) (2004) (8)
- Practical guidelines for drug holidays in parkinsonian patients (1981) (8)
- Seminal figures in the history of Movement Disorders: Sydenham, Parkinson, and Charcot: Part 6 of the MDS‐sponsored history of Movement Disorders exhibit, Barcelona, June 2000 (2001) (7)
- Disappearance of a putative DA-neuron antibody following adrenal medulla transplantation: relationship to a striatal-derived DA neuron trophic factor. (1990) (7)
- Medical-legal issues in Charcot’s neurologic career (2004) (7)
- Gender‐, age‐, and race/ethnicity‐based differential item functioning analysis of the movement disorder society–sponsored revision of the Unified Parkinson's disease rating scale (2016) (7)
- Measuring Medication Adherence in Parkinson's Disease: A Systematic Review of Contributing Components in Rating Scales (2020) (7)
- History of Myoclonus: Part 8 of the MDS‐sponsored history of Movement Disorders exhibit, Barcelona, June 2000 (2001) (7)
- [Charcot: a scientific Janus]. (1994) (7)
- MDS-UPDRS use in the COVID era. (2020) (7)
- Validizácia slovenskej verzie Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) (2013) (7)
- Animal Models of Tardive Dyskinesias (1983) (7)
- Seminal figures in the history of Movement Disorders: Hammond, Osler, and Huntington. Part 11 of the MDS‐sponsored history of Movement Disorders exhibit, Barcelona, June 2000 (2001) (6)
- Independent Spanish Validation of the Unified Dyskinesia Rating Scale (2014) (6)
- DA agonists ‐ Non‐Ergot derivaties: Ropinirole (2002) (6)
- Movement Disorders, Overview (2003) (6)
- Comparison of the Movement Disorder Society Parkinson's disease dementia criteria with neuropsychological testing (2014) (6)
- The Movement Disorder Society and Movement Disorders: A Modern History (2011) (6)
- Charcot and aphasia. (1996) (6)
- Charcot in Contemporary Literature (2006) (6)
- The Brown–Séquard and S. Weir Mitchell Letters (2001) (6)
- DA agonists ‐ Ergot derivaties: Cabergoline (2002) (6)
- Controversies in animal models of tardive dyskinesia (1981) (6)
- Diagnosis of Tardive Dyskinesia (1983) (6)
- It's tricky: Rating alleviating maneuvers in cervical dystonia (2020) (6)
- Development of instruments for abnormal movements: Dynamometers, the dynamograph, and tremor recorders. Part 9 of the MDS‐sponsored History of Movement Disorders exhibit, Barcelona, June 2000 (2001) (6)
- Delayed onset of progressive dystonia following subacute 3-nitropropionic acid treatment in Cebus apella monkeys. (2000) (6)
- Psychosocial counseling in Parkinson's disease (2002) (6)
- Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale. (2017) (6)
- Surgical treatment for Parkinson's disease: Neural transplantation (2002) (6)
- Early Iconography of Parkinson's Disease (2003) (5)
- Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change (2021) (5)
- Head tremor and pain in cervical dystonia (2021) (5)
- L-5-HTP-induced myoclonic jumping behavior in guinea pigs: an update. (1986) (5)
- Shaking up the Salpêtrière (2010) (5)
- Charcot at the Salpêtrière (1987) (5)
- Posthypoxic myoclonus in the rat: Natural history, stability, and serotonergic influences (2000) (5)
- Physical and occupational therapy in Parkinson's disease (2002) (5)
- The effect of thioridazine on haloperidol induced behavioral hypersensitivity. (1986) (5)
- Toward the use of surgical placebo-controlled trials. (1997) (5)
- Shakespeare in Charcot's neurologic teaching. (1988) (5)
- Methods of Patient Assessment in Surgical Therapy for Movement Disorders (2003) (5)
- The role of surgery in Parkinson's disease management (1994) (5)
- A child with recurrent episodes of involuntary movements (1999) (5)
- Multi‐infarct PSP (1987) (5)
- Psychosis in Parkinson’s disease (2009) (5)
- Gut microbial metabolites in Parkinson’s disease: Association with lifestyle, disease characteristics, and treatment status (2022) (5)
- What is it? Case 2, 1988. Congenital mental retardation and juvenile parkinsonism (1988) (5)
- Levodopa drug holiday versus drug dosage reduction in Parkinson's disease (1994) (4)
- DA agonists ‐ Non‐Ergot derivaties: Apomorphine (2002) (4)
- Subject-investigator reproducibility of the Unified Parkinson's Disease Rating Scale. (2012) (4)
- Movement disorders: understanding clinical trials (2005) (4)
- Differential item functioning in the Unified Dyskinesia Rating Scale (UDysRS) (2017) (4)
- Corrigendum: Fatigue in Parkinson’s disease: report from a multidisciplinary symposium (2017) (4)
- Neuroleptic-Induced Movement Disorders (2008) (4)
- Georges Guillain's neurologic exploration of America (1998) (4)
- The predictive value of acute antimuscarinic drugs for the chronic efficacy of antimuscarinic drugs in adults with focal dystonia. (1988) (4)
- Update on Treatments for Motor Symptom of Pd (4)
- Does Added Objective Tremor Monitoring Improve Clinical Outcomes in Essential Tremor Treatment? (2018) (4)
- MYOCLONUS, METHYSERGIDE, AND SEROTONIN (1974) (4)
- History of movement disorders as a neurological specialty: Part 14 of the MDS‐sponsored History of Movement Disorders exhibit, Barcelona, June 2000 (2001) (4)
- The Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT‐PD): Tolerability of Preoperative Neuropsychological Testing for Deep Brain Stimulation in Parkinson's Disease (2015) (4)
- Reliability of the Severity subscale of the revised Toronto Spasmodic Torticollis Rating Scale (TWSTRS-2) (S15.001) (2015) (4)
- The election of Sarah McNutt as the first woman member of the American Neurological Association. (2002) (4)
- A grateful thank you (2005) (4)
- Head tremor in cervical dystonia: Quantifying severity with computer vision (2022) (4)
- Reply: MoCA for cognitive screening in Parkinson's disease: Beware of floor effect (2018) (3)
- DA agonists ‐ Ergot derivaties: Lisuride (2002) (3)
- Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (2022) (3)
- Development of instruments for abnormal movements: Postural sway and gait analyses. Part 10 of the MDS‐sponsored history of Movement Disorders exhibit, Barcelona, June 2000 (2001) (3)
- Non‐motor phenotypic subgroups in adult‐onset idiopathic, isolated, focal cervical dystonia (2021) (3)
- The pathology of hallucinations: one or several points of processing breakdown? (2014) (3)
- Novel Approach to Movement Disorder Society–Unified Parkinson's Disease Rating Scale Monitoring in Clinical Trials: Longitudinal Item Response Theory Models (2021) (3)
- Smoking and Nicotine (2003) (3)
- Risk factors for nursing home placement in advanced Parkinson's disease (1993) (3)
- The treatment of tics (2004) (3)
- Authors' responsibilities: No ghost writing (2005) (3)
- Evidence for Multiple Genes (2001) (3)
- Parkinsonism‐plus syndromes: Part 7 of the MDS‐sponsored history of Movement Disorders exhibit, Barcelona, June 2000 (2001) (3)
- Jean–Martin Charcot (1825–1893) (2005) (3)
- Treating melancholia at home (2013) (3)
- Pharmacology of Animal Neurotoxins (1982) (3)
- Early cinematographic studies of generalized dystonia (2006) (3)
- Silas Weir Mitchell (1829–1914) (2002) (3)
- Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia? (2021) (3)
- Biological neurotoxins. (2000) (3)
- The basal ganglia: Part 1 of the MDS‐sponsored History of Movement Disorders Exhibit, Barcelona, June 2000 (2001) (3)
- Charcot and the myth of misogyny (1999) (3)
- Sinemet skin rash. (1984) (3)
- New version of the UPDRS: Development methods and working document for field testing (2005) (3)
- Closing the celebration of 200 years of Parkinson's Essay on the Shaking Palsy: Where do we go in the next 200 years? (2017) (3)
- Fetal-tissue transplantation for Parkinson's disease. (1993) (2)
- Tai chi for patients with Parkinson's disease. (2012) (2)
- Historical Interfaces Between American Neurology and Psychiatry (2006) (2)
- Gut-Brain Communication in Parkinson’s Disease: Enteroendocrine Regulation by GLP-1 (2022) (2)
- Historical Issues and Atypical Parkinsonian Disorders (2005) (2)
- Facing the unique challenges of dyskinesias in Parkinson’s disease (2012) (2)
- Charcot: Past and present. (2017) (2)
- Assessment of Non‐Motor Features of Parkinson's Disease: Scales and Rating Tools (2011) (2)
- Reply to: Cognitive Effects of Deep Brain Stimulation in GBA‐Related Parkinson's Disease (2022) (2)
- Relationship of Movement Disorders Society–Unified Parkinson's Disease Rating Scale Nonmotor Symptoms to Cognitive Functioning in Patients with Parkinson's Disease (2020) (2)
- Eye signs and tic disorders: Gilles de la Tourette's syndrome. (1997) (2)
- Annual Meeting of the American Academy of Neurology (2002) (2)
- Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling (2022) (2)
- Hold that pose: capturing cervical dystonia's head deviation severity from video (2022) (2)
- Torsion dystonia in children (2003) (2)
- The Use of Dopamine Agonists and Antagonists in Neurology (1984) (2)
- Attenuated Postprandial GLP-1 Response in Parkinson’s Disease (2021) (2)
- Missing Data in the Unified Dysksinesia Rating Scale (UDysRS) (2018) (2)
- Criteria for Prodromal Parkinson ’ s Disease (2015) (2)
- It Is as It Was: MDS‐UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum (2022) (2)
- Genetic Variation Analysis in Parkinson Disease Patients With and Without Hallucinations (2017) (2)
- Highlights of the North American and European experiences (1998) (2)
- PRODEST study: depressive symptoms in Parkinson's disease (2007) (2)
- Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version (2007) (2)
- Therapies for movement disorders. (2002) (2)
- Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice? (2021) (2)
- Gilles de la Tourette’s Syndrome and Tic Disorders (2000) (2)
- Controlled‐release Sinemet (1987) (2)
- Progression of Parkinson's disease (1989) (2)
- Estrogen Supplementation in the Posthypoxic Myoclonus Rat Model (2001) (2)
- The effect of chronic levodopa on haloperidol induced behavioral supersensitivity in the guinea pig. (1981) (1)
- Validation of the Finnish Version of the Unified Dyskinesia Rating Scale (2021) (1)
- Minds Behind the Brain: A History of Brain Pioneers and Their Discoveries (2000) (1)
- Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings (2023) (1)
- Gait and Gait Disorders (2014) (1)
- From Null to Midline: Changes in Head Posture do Not Predictably Change Head Tremor in Cervical Dystonia (2022) (1)
- Parkinson's Disease and Movement Disorders (1998) (1)
- Prodest - Depressive symptoms in Parkinson's disease: Demographic data (2007) (1)
- The role of the serotonin system in animal models of myoclonus. (2002) (1)
- Implementation and Outcomes of a Movement Disorder Society‐Sponsored Peer Reviewing Education and Mentoring Program (2022) (1)
- Sudden death in Moersch‐Woltman (1984) (1)
- Weekly drug holiday in PD (1982) (1)
- Dystonia in FMR1 Premutation Carriers (P01.222) (2012) (1)
- The stability of carbidopa in solution (1997) (1)
- Drs. Goetz and Klawans Reply (1981) (1)
- Relationship of aluminum to neurocognitive dysfunction in chronic dialysis patients. (1988) (1)
- EFFECTS OF CENTRAL DOPAMINERGIC STIMULATION BY APOMORPHINE ON VOCAL PARAMETERS IN PARKINSON'S DISEASE (1999) (1)
- Complications of chronic levodopa therapy (1981) (1)
- Will Artificial Intelligence Outperform the Clinical Neurologist in the Near Future? No (2021) (1)
- The Parkinson's disease multidisciplinary package (2013) (1)
- Apathy , fatigue and quality of life in patients with Parkinson ' s disease (2018) (1)
- Chapter 11: Pharmacology of Minimal Brain Dysfunction (1978) (1)
- An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants (2023) (1)
- Huntington's Disease: Current Concepts of Therapy * (1979) (1)
- DA agonists ‐ Non‐Ergot derivaties: Pramipexole (2002) (1)
- MDS-Sponsored Scale Translation Program: Process, Format, and Clinimetric Testing Plan for the MDS-UPDRS and UDysRS (P2.052) (2014) (1)
- Unified Dyskinesia Rating Scale (2016) (1)
- Relationship between the MDS-UPDRS and Quality of Life in Parkinson's Disease: a large international multicenter Study (the QUALPD study) (2016) (1)
- MDS‐UPDRS Motor Examination retains its two‐domain profile in both ON and OFF (2022) (1)
- [Where are the grafts in Parkinson's disease?]. (1989) (1)
- DA agonists ‐ Ergot derivaties: Dihydroergocryptine (DHEC) (2002) (1)
- Parkinson's disease. (1999) (1)
- Validation of the Arabic Version of the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale (2022) (1)
- How Do I Test for Postural Stability? (2014) (1)
- Telemedicine vs Office visits in a Movement Disorder Specialty Clinic: Comparative Satisfaction of physicians and patients. (P4.003) (2017) (1)
- Movement Disorders Induced by Neuroleptic Drugs (1986) (1)
- Temporary levodopa withdrawal. (1986) (1)
- Chronic agonist‐induced hypersensitivity and on‐off hyperkinesis (1979) (1)
- Remembrance of Things Past: A Critical Step in Changing our Future (2021) (1)
- Rating scales for medication adherence in people living with Parkinson's disease: a systematic review protocol. (2021) (1)
- DA agonists ‐ Non‐Ergot derivaties: Piribedil (2002) (1)
- Historical Issues in the Study of Behavioral Dysfunction in Movement Disorders (2003) (1)
- Progressive Supranuclear Palsy (PSP) (2003) (1)
- PSYCHIATRIC REACTION TO ERGOT DERIVATIVES (1979) (1)
- Eminent Neuroscientists: Their Lives and Works by Kalyan B. Bhattacharyya Academic Publishers. 2012 (2013) (1)
- Babinski's contributions to cerebellar symptomatology: building the basis of the neurological examination. (2013) (1)
- [Progressive supranuclear palsy]. (2003) (1)
- Foreword (2016) (1)
- New approaches in the treatment of the dystonias (1990) (1)
- The Influence of Shakespeare on Charcot's Neurological Teaching (2004) (1)
- Hallucinogens: Neurochemical, Behavioral, and Clinical Perspectives, edited by Barry L. Jacobs (Central Nervous System Pharmacology Series). Raven Press, New York, 1984, 248 pp., $54.50 (1985) (1)
- Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Overview of Parkinson's disease: epidemiology, diagnosis, course, medical and surgical management (2013) (1)
- Validation of the Hebrew Version of the Unified Dyskinesia Rating Scale (2020) (1)
- Cognitive Deficits in Veterans with Parkinson’s Disease: A National Database Analysis (P5.262) (2014) (1)
- Greeting from the new editors (2004) (1)
- Novel approach to MDS‐UPDRS monitoring in clinical trials: Longitudinal Item Response Theory Models (2021) (1)
- A HISTORY OF MADNESS IS SUPERFICIALLY BRIEF (2002) (1)
- Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice. (2023) (0)
- The plight of loneliness in Parkinson's disease: New opportunities. (2022) (0)
- GOETZ, Christopher: Illinois/USA (2019) (0)
- Letters to the Editor (1997) (0)
- Cross‐Cultural Differences in Patient Perceptions of Dyskinesia in Parkinson's Disease (2023) (0)
- Editorial (0)
- Preface. (2020) (0)
- Responsivity of the Fragile X-Associated Tremor Ataxia Syndrome Rating Scale (P05.034) (2013) (0)
- Understanding visual hallucinations: a new synthesis. (2023) (0)
- パーキンソン病におけるプラセボ反応--内科的・外科的介入に関する11の臨床試験の比較 (2008) (0)
- Validation of the Polish version of the Unified Dyskinesia Rating Scale (UDysRS). (2021) (0)
- Surgery for PD (1993) (0)
- Developing Skills That Serve Our Journal, Your Colleagues as Potential Authors, and You (2019) (0)
- Electrical and Lightning Injuries (2003) (0)
- [Botulin toxin: principles of action and neurological indications]. (1997) (0)
- SURGERY FOR PD. AUTHOR'S REPLY (1993) (0)
- Modified out patient drug holiday in the management of parkinsonism (1981) (0)
- Organophosphates, Organochlorides, and Pesticides (2003) (0)
- Parkinson’s Disease Medication Adherence Scale: Conceptualization, Scale Development, and Clinimetric Testing Plan (2022) (0)
- Comprar Textbook of Clinical Neurology | Christopher G. Goetz | 9781416036180 | Saunders (2007) (0)
- Fatigue in Parkinson's Disease (P06.052) (2012) (0)
- Dramatic science or scientific drama? (2017) (0)
- The State of Drug Trials for Parkinson's Disease Treatments (2002) (0)
- Learning from the Latest: Failures and Successes in Movement Disorders Trials (2014) (0)
- Apathy in Parkinson disease (2020) (0)
- Medical art and photography in the history of movement disorders: Part 13 of the MDS‐sponsored History of Movement Disorders exhibit, Barcelona, June 2000 (2001) (0)
- Maynard M. Cohen, MD, PhD (1920–2014) (2014) (0)
- Intestinal microbiota and neuroinflammation in Parkinson's disease: At the helm of the gut-brain axis. (2022) (0)
- Alcohol-Related Neurotoxicity (2003) (0)
- Treating Melancholia in the Home: Theoretical Wisdom and Grim Reality in the Career and Life of EC Seguin (S57.003) (2013) (0)
- III.1 Differential diagnosis in psychosis in Parkinson's Disease patients (2006) (0)
- Motor System; Overview (2014) (0)
- Comprar Neurology for the Non-Neurologist 6ed | Christopher G. Goetz | 9781605472393 | Lippincott Williams & Wilkins (2010) (0)
- Fragments of Neurological History (2004) (0)
- Two faces of the teacher: Comparing editions of Charcot’s Leçons du mardi (2022) (0)
- Paroxysmal Movement Disorders (2003) (0)
- Drugs to treat gastrointestinal motility problems (2002) (0)
- Achieving interrater reliability in Parkinsons disease Utility of the movement disorder society-owned teaching tape of the unified Parkinsons disease rating scale (2003) (0)
- DA agonists ‐ Overview (2002) (0)
- S149 Patient-Derived Enteroids and Colonoids for Measuring Enteroendocrine Function in Response to Luminal Contents: A Proof-of-Concept Study in Parkinson’s Disease (2022) (0)
- White Matter Hyperintensities Successfully Differentiate Parkinson's Disease Patients with and without Cognitive Impairment (P06.050) (2013) (0)
- Charcot and automatisms (1988) (0)
- Continuous Home Monitoring of Essential Tremor Using Motion Sensors (P05.035) (2013) (0)
- Book Review A Cursing Brain? The histories of Tourette syndrome By Howard I. Kushner. 303 pp. Cambridge, Mass., Harvard University Press, 1999. $29.95. 0-674-18022-4 (1999) (0)
- Relationship between the MDS-UPDRS and Quality of Life : a large international multicenter study of 3206 patients (2018) (0)
- Multisystem Atrophy (MSA) (2014) (0)
- Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine (2022) (0)
- Falls and Drops (2003) (0)
- Re: Hypothyroidism and Parkinson's disease (2004) (0)
- Successful use of the Unified Dyskinesia Rating Scale regardless of PD- or dyskinesia-duration. (2019) (0)
- Assessment and treatment of drug-induced tremor. (1980) (0)
- Letters to the editor (0)
- Movement Disorders: Parkinson's Disease (2014) (0)
- Determining Optimal Cutoff Scores and Neuropsychological Tests for the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease (S37.003) (2014) (0)
- Hemiparkinsonism and hemiatrophy (1988) (0)
- Elevated Body Aluminum Stores Correlate with Cognitive and Motor Dysfunction in Chronic Dialysis (1987) (0)
- Fragile X-associated tremor ataxia syndrome rating scale: Revision and content validity using a mixed method approach (2022) (0)
- Dyskinesia Rating Scales in Parkinson’s Disease (2014) (0)
- 1.167 PRODEST – Depressive symptoms in Parkinson's disease: Pattern across scales (2007) (0)
- Charcot and Pasteur: Intersecting Orbits in Fin de Siècle French Medicine (2009) (0)
- 641 Accuracy of the clinical diagnosis of pick's disease (1996) (0)
- In Memoriam Harold L. Klawans, M.D (1998) (0)
- O.030 Scales to evaluate psychosis in Parkinson's disease (2009) (0)
- Dyskinesias in Parkinsonian Syndromes (2012) (0)
- V.7 fMRI studies of psychosis in Parkinson's Disease (2006) (0)
- Response to letter by Saenz‐Farret et al. on “Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations” (2017) (0)
- Hallucinations And Dementia In Parkinson’s Disease: Clinically Related But Structurally Distinct (P5.257) (2014) (0)
- Movement disorders offers electronic manuscript submission (2003) (0)
- Movement Disorder Society Unified Parkinson's Disease Rating Scale Motor Examination Retains Its 2‐Domain Profile in Both On and Off States (2022) (0)
- Reply: Hoehn and Yahr stage 3 and Postural stability item in the Movement Disorder Society‐Unified Parkinson's Disease Rating Scale (2018) (0)
- University of Groningen Apathy , fatigue and quality of life in patients with Parkinson ' s disease (2017) (0)
- Errors and editorial vigilance (2008) (0)
- Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
- Book Review Treating Tourette Syndrome and Tic Disorders: A Guide for Practitioners Edited by Douglas W. Woods, John C. Piacentini, and John T. Walkup. 287 pp. New York, Guilford Press, 2007. $38. 978-1-59385-480-5 (2007) (0)
- Observing the link between speech production and speech perception from disordered speech (2000) (0)
- Editorial (0)
- Writer's Cramp/Tremor (2003) (0)
- Q: My husband has Parkinsonʼs disease and seems depressed. What should I do? (2005) (0)
- Reply (1987) (0)
- Psychogenic Movement Disorders (2010) (0)
- In Memory of Dr. William J. Weiner (2013) (0)
- Characterization of Tau Association with Parkinson's Disease (2003) (0)
- Preface (2015) (0)
- Clinical presentation and pharmacological therapy in cortico-basal ganglionic degeneration (1996) (0)
- Disclosure on author work effort (2007) (0)
- In Support of Electronic Versions of Movement Disorder Society Rating Scales (2021) (0)
- Books Received (2001) (0)
- Handling Missing Values in the MDS-UPDRS (P1.195) (2015) (0)
- STABILITY OF LEVODOPA/CARBIDOPA SOLUTIONS. AUTHORS' REPLY (1997) (0)
- Placebo Response in Fragile X‐associated Tremor/Ataxia Syndrome (2020) (0)
- Motor System, Overview (2003) (0)
- Hyperkinetic movement disorders (2015) (0)
- Harold L. Klawans, MD (1998) (0)
- The use of cosmetic surgical placebo controlled trials (1996) (0)
- Concerning about the accuracy of data reported. (2008) (0)
- Comparison of Movement Disorder Society Criteria for Parkinson's Disease Dementia with Routine Clinical Neuropsychological Testing (PD4.006) (2012) (0)
- Rating Scales for Medication Adherence in Parkinson's Disease: A Systematic Review for Critique and Recommendations (2022) (0)
- The Rush Video‐Based Tic Rating Scale‐Revised : a practice‐oriented revision (2023) (0)
- Are Virtual Objective Assessments of Fall‐Risk Feasible and Safe for People with Parkinson's Disease? (2022) (0)
- [Fetal and adrenal transplantation in Parkinson disease: theoretical bases and clinical results]. (1993) (0)
- New Journal Continuing Medical Education (CME) Program (2006) (0)
- Iconographies supplémentaires de l'article : Charcot: Past and present (2017) (0)
- CPK values in Parkinson's disease. (1981) (0)
- Reply (1981) (0)
- Everolimus in HR-Positive Advanced Breast Cancer (2012) (0)
- Discoveries in the Human Brain: Neuroscience Prehistory, Brain Structure, and Function (1998) (0)
- The effect of bromocriptine (BCT) on the on-off phenomenon (2005) (0)
- Jean-Martin Charcot and the opening of the French medical hierarchy to women (2017) (0)
- Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) (S27.004) (2014) (0)
- Effects of central dopaminergic stimulation by apomorphine on producing sentence focus in speech production in Parkinson’s disease—a preliminary report (2000) (0)
- Bookshelf: Charcotʼs Saga with Hysteria Retold — Both Refreshing and Balanced (2011) (0)
- Documentation of Cognitive Diagnoses in Parkinson's Disease Following Deep Brain Stimulation (P04.182) (2013) (0)
- Apathy in Parkinson's disease: Why we should care. (2020) (0)
- Passing of the Baton (2003) (0)
- No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
- Genetics of Neurogenic Orthostatic Hypotension in Parkinson’s Disease, Results from a Cross-Sectional In Silico Study (2023) (0)
- DA agonists ‐ Ergot derivaties: Bromocriptine (2002) (0)
- The frequency of PARKIN, LRRK2, GBA in early onset Parkinson disease patients who receive deep brain stimulation (P2.148) (2015) (0)
- Freud ’ s Comparative Study of Hysterical and Organic Paralyses How Charcot ’ s Assignment Turned Out (2003) (0)
- Sequential drug holiday in Parkinson's disease (1984) (0)
- [History of dystonia]. (2001) (0)
- Excitotoxins and Excitotoxicity (2003) (0)
- Neurodegenerative Diseases: Approach to the patient presenting with parkinsonism (2005) (0)
- Progressive cognitive decline with truncal/limb ataxia and ballistic movements (1997) (0)
- Chairmen's Letter 2 Primary and Associated Faculty Department of Neurological Sciences 4 Primary and Associated Faculty Department of Neurological Surgery 7 Fellows and Residents Department of Neurological Sciences 8 Fellows and Residents Department of Neurological Surgery 9 Articles Faster Cognitiv (2014) (0)
- Unified Dyskinesia Rating Scale: Candidate for Official Designation of FDA Designation as Qualified Clinical Outcome Assessment (P1.023) (2016) (0)
- Movement Disorders due to Systemic Disease (2013) (0)
- New version of the UPDRS (MDS-UPDRS): Factor analysis (2008) (0)
- Reply (1997) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Christopher. G. Goetz?
Christopher. G. Goetz is affiliated with the following schools:
